Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based Founder operating in the Health Care space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
David Yu Zhang
Co-Founder & Head of Innovation of NuProbe
David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.
Follow David Yu Zhang:
About NuProbe: An early stage molecular diagnostics company.
_______
Peng Yin
Co-Founder, Director of NuProbe
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Co-Founder, Director at Torus Biosystems.
Follow Peng Yin:
About Harvard Medical School, NuProbe, Torus Biosystems, Ultivue, Wyss Institute: An early stage molecular diagnostics company.
Yingshuang Chai
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Yundi Chen
Co-Founder of NuProbe
Yundi Chen is a Co-Founder at NuProbe.
Follow Yundi Chen:
About NuProbe: An early stage molecular diagnostics company.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Nichola Eliovits
Co-Founder, Chief Business Officer of DermBiont
Nick’s investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital. Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries. His passion for the Microbiome originates from personal experiences with skin infections and c-diff. Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.
Follow Nichola Eliovits:
About DermBiont, Popover: DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
Todd Dagres
Chairman and Founder of Liteboxer
Todd Dagres is the Chairman and Founder at Liteboxer.
Follow Todd Dagres:
About Liteboxer, Signpost, Spark Capital: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
Jeffrey Morin
Co-Founder and CEO of Liteboxer
Jeffrey Morin is the founder and CEO of Liteboxer.
Follow Jeffrey Morin:
About Liteboxer: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
Lanny Sun
Co-Founder & CEO of Silicon Therapeutics
Follow Lanny Sun:
About Silicon Therapeutics: Silicon Therapeutics is a fully integrated drug design, research, and development company.
Nessan Bermingham
Founder, CEO & currently Exec Chair of Triplet Therapeutics
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Follow Nessan Bermingham:
About Korro Bio, Triplet Therapeutics: Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Alexis Borisy
Co-Founder of Blueprint Medicines
Alexis Borisy is the Chairman of the Board of Directors & Co – Founder of Foundation Medicine Inc.He is also a Partner at Third Rock Ventures.Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science-based organizations. Alexis Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He co-founded Foundation Medicine and served as the company’s interim CEO through May 2011.Prior to joining Third Rock Ventures, Alexis Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis Borisy was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.Alexis Borisy’s Undergraduate Degree in Chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis Borisy serves on the Board of the Biotechnology Industry Organization, is an Overseer at the Boston Museum of Science, is the Chairman of Forma Therapeutics, and serves on the board of Blueprint Medicines.
Follow Alexis Borisy:
About Blueprint Medicines, Blueprint Medicines, EQRx, Third Rock Ventures: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Mirza Cifric
Co-Founder & Chief Executive Officer of Veritas Genetics
Follow Mirza Cifric:
About Veritas Genetics, YPO: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Anna Villarreal
Founder & CEO of LifeStory Health Inc
Leading the first-ever discovery research into the clinical utility of menstrual blood, a recent Proof of Principle study resulted in findings of unique signatures specific to menstrual blood. On-going clinical studies aim to develop the diagnostic science further in order to support our preliminary pipeline. Anna’s resourceful leadership style and entrepreneurial experience has lead LifeStory Health, Inc. through remarkable discoveries and growth in a very short time when compared to most bioscience companies. She attributes this to her steadfast passion for and about Women’s Health. A strong advocate for women’s healthcare, Anna’s pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award winning scientific methodology has led to biomarker discovery based on precision medicine. Anna guest lectures for several graduate level programs at Northeastern University including data analytics, chemistry, regulatory affairs, and master’s in business administration. She teaches her own class in the Master’s of Biotechnology Program titled “Women’s Health: Driving Innovation and Cultural Change”. Her advocacy for women’s health continues on her podcast, “Setting the Pace”, in which she and her co-host highlight fellow female innovators.
Follow Anna Villarreal:
About CEOWORLD Magazine, LifeStory Health Inc, NEFC, The Doctor Weighs In: LifeStory Health is a biotech company committed to changing the women’s healthcare market through technology, innovation and vocalization.
Terry Anderton
Founder and CEO of WAGZ
Terry Anderton is the founder and CEO of Wagz and a lifelong dog owner. Terry has a long history of building disruptive and forward-thinking technology companies, including Gemr, a social commerce platform; Trunity, a cloud-based textbook company he took public in 2012; and NitroSecurity, a network security developer acquired by Intel in 2011. Terry has also served as a Senior Sales Executive for Cabletron Systems and McAfee. He started his career leading world wide sales and launching the game of Paintball for the inventor of the game.
Follow Terry Anderton:
About WAGZ: Helping humans stay connected to their dogs through the world’s smartest dog collar.
Shantanu Gaur
Co-Founder & CEO of Allurion Technologies
Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scientific Officer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and significant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.
Follow Shantanu Gaur:
About Allurion Technologies, Genetic Alliance: Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Garry Choy
Co – Founder of andros
Dr. Garry Choy, MD, MBA, is Q’s Chief Medical Officer. Prior to joining Q he was faculty at Harvard Medical School / Mass General Hospital where he held leadership positions in enterprise and imaging informatics including as Assistant Chief Medical Information Officer, Director of the Medical Imaging Trials Center, and Medical Director for MGH-QPID Analytics. Recipient of a number of grants and awards in applying machine learning to healthcare from the ACR, CRICO, and RSNA. Previously a research scholar focused on advanced imaging techniques at the National Institutes of Health and Howard Hughes Medical Institute. Completed MD from Albert Einstein College of Medicine and residency training at Harvard-based Brigham and Women’s Hospital and Massachusetts General Hospital. Completed MBA from Hopkins, MS in Economic Engineering Systems & Operations Research from Stanford, and BS in Chemical Engineering from Columbia University.
Follow Garry Choy:
About andros, Massachusetts General Hospital, Q Bio: andros is a provider of network management solutions for healthcare organizations.
Derek Lo
Founder and CEO of Medallion
Derek Lo Founder and CEO of Medallion. He was previously co-founder and CEO at Py. He earned his bachelor’s degree in computer science and statistics from Yale University.
Follow Derek Lo:
About Hired, Medallion: Medallion provides a network management platform for the healthcare industry.
Ravi Ika
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
Todd Cozzens
Co-Founder & Managing Partner of Transformation Capital
With more than 25 years of experience in the healthcare technology and information systems industry, Todd Cozzens is a senior advisor with Silicon Valley-based Sequoia Capital, a premier venture-capital firm with a long track record in technology investing. Most recently Cozzens served as the CEO of the accountable care solutions unit of Optum, part of UnitedHealth Group. Cozzens co-founded Picis, the leading high acuity information system company. It was Cozzens’ original strategic vision of information systems for the high-acuity care areas of hospitals that drove the company to a 50% annual growth rate over a ten year span and to over 2100 hospital clients. He was named Entrepreneur of the Year by Ernst & Young in 2005. Prior to Picis, Cozzens served as the president of a division of Marquette Medical Systems (now GE Healthcare) and held several other senior management positions, including vice president of sales, from 1983 to 1995. Cozzens is a graduate of Marquette University and the Harvard Business School Executive Program for Management Development. He was a four-time member of the U.S. Olympic Sailing Team from 1980 to 1992.
Follow Todd Cozzens:
About Transformation Capital: Transformation Capital is a growth equity fund 100% focused on innovative healthcare IT and services companies.
Jared Kesselheim
Co-Founder & Managing Partner of Transformation Capital
Jared Kesselheim, MD, brings to Transformation Capital more than fifteen years of investing and clinical experience and has a demonstrated history of identifying compelling companies and helping them realize continued innovation, growth and strong exits. Jared co-founded Transformation Capital’s predecessor management company in 2016 and serves on the boards of six Fund I portfolio companies: Vera Whole Health, Scientist.com, Aktana, Protenus, Groups, and Panalgo. Previously, Jared was at Bain Capital Ventures, where he was a leader of their digital health practice, focusing on investments in digital health as part of an $850 million multi-sector fund. He became a Partner of Bain Capital Ventures in January 2014, having previously served as an Associate and Principal after joining that firm in July 2008. During his time at Bain Capital Ventures, Jared was involved in multiple high growth investments including: Apixio (Board Director), Remedy Partners (Board Observer; acquired by New Mountain Capital in 2019), ABILITY Network (Board Director after being Board Observer; acquired by Summit Partners in 2014 and acquired by Inovalon in 2018), MedHOK (Board Observer; acquired by Hearst in 2016), National Cardiovascular Partners (Board Observer; acquired by Fresenius in 2014), and Liazon (Board Observer, acquired by Towers Watson in 2014). Prior to his investing career, Jared completed a residency in Internal Medicine at Massachusetts General Hospital. As a resident physician, he oversaw a primary care panel of 300 patients and directed care teams within the hospital’s general medical wards and the medical intensive care unit. Jared graduated from Harvard College summa cum laude and Phi Beta Kappa with a degree in Biochemical Sciences, where he also co-wrote the 1997 Hasty Pudding Theatricals musical “Me and My Galaxy.” He also received an MD from Harvard Medical School and an MBA from Harvard Business School where he was a Baker Scholar and an enthusiastic bench warmer for the HBS Club Hockey team. At home in Newton, Massachusetts, Jared and his wife Dara continue to work in vain on developing strategies for preventing their three young boys from treating all furniture as a form of playground equipment.
Follow Jared Kesselheim:
About Transformation Capital: Transformation Capital is a growth equity fund 100% focused on innovative healthcare IT and services companies.
Ryan Boyko
Founder & CEO of Embark
Ryan Boyko is the CEO and co-founder of Embark Veterinary, Inc. Since graduating from Harvard in 2005 with a BA in Computer Science, he has used Big Data analyses to further scientific research and business development across a number of fields before targeting consumer canine genetics. After receiving an MS in Ecology and MA in Evolutionary Anthropology from the University of California at Davis, he worked to develop Big Data retail consulting analytics for Oliver Wyman. He is currently also completing a PhD in the Epidemiology of Microbial Diseases at the Yale School of Public Health. Since 2007, he has worked part time with his brother Adam on understanding the history and genetics of the domestic dog. This work has sent him to over three dozen countries and led to several publications. He has now chosen to pursue advancing canine health and genetic understanding full-time, building a company to put develop and promote the health and genetic understanding of man’s best friend.
Follow Ryan Boyko:
About Embark: Embark offers dog DNA testing that ends preventable diseases in dogs.
Adam Sachs
Co-Founder and CEO of Vicarious Surgical
Follow Adam Sachs:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Helen Adeosun
Founder & CEO of CareAcademy
Helen is CEO and Co-Founder at CareAcademy.com. She is passionate about caregiving and the impact that the right caregiver can have on families. Prior to this, Helen had worked with Teach for America, Boston Public Schools, and Pearson Education as well as a number of companies focused on caregiving issues. Care Academy was born out of her own experience as a nanny and she hopes that sittercycle.com is a place to continuously learn and share with current and future nannies. She holds a B.A. from the University of Notre Dame and an EdM. from the Harvard Graduate School of Education.
Follow Helen Adeosun:
About CareAcademy: Online training empowering senior care professionals to deliver the highest caliber of service and improve the lives of older adults.
Elizabeth Pattullo
Chairman and Founder of Beacon Health Strategies
Elizabeth Pattullo, one of Beacon’s founders, is responsible for all strategic and business development activities. Creating the business concept of delivering client-focused, cost effective behavioral health services, Ms. Pattullo has grown Beacon into a company that manages more than seven million members in 14 states. Having lectured at both the Heller School at Brandeis University and Harvard University Medical School, Ms. Pattullo has more than 30 years of public and private sector management experience in complex and highly-charged environments. As executive director for Mental Health Management of America (MHMA), she administered the first and largest carve-out of mental health and substance use disorder services for Medicaid enrolled clients in the country. Under her leadership, MHMA improved treatment outcomes while reducing overall costs by $50 million. Ms. Pattullo earned her M.Ed. from Harvard University.
Follow Elizabeth Pattullo:
About Beacon Health Strategies: Beacon Health Strategies is engaged in the development and management of mental health and substance abuse programs for hospitals.
Christopher McCann
CEO & Co-Founder of Current Health
I left school at the age of 16 and graduated with a Masters in Computer Science at age 21. At 20, I set up my first company, Dizeo – this was in social networking for children. This failed in 2011 but the experience taught me some of the most valuable lessons of my life. Around the same time, I was spending time in hospitals due to an unwell relative. I decided to go to medical school as a result in 2012. In 2014, I founded snap40 as a direct result of my experiences working in hospital. I was part of the care of patients who had deteriorated avoidably because the warning signs were detected late. I wanted a world where myself and my family would be treated preventatively at the earliest possible point. snap40 prevent illness by automatically detecting those at high risk. We’re a software company who uses our own wearable device, worn on the upper arm of the patient, to continuously monitor them. We then do predictive analytics to identify the patient who needs medical attention most and bring healthcare to them, far earlier. Please get in touch! E-mail: christopher@snap40.com
Follow Christopher McCann:
About Current Health: We help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.
Ted Tieken
Founder and CEO of Keto and Co
Ted is the Founder and CEO of Keto and Co / Sated. Formerly cofounder and CTO of SittingAround.com
Follow Ted Tieken:
About Keto and Co, SittingAround: Keto and Co makes a growing line of ultra-low carb, ketogenic foods.
Rushika Fernandopulle
Co-Founder & Chief Executive Officer of Iora Health
Rushika Fernandopulle is Co-founder and CEO at Iora Health
Follow Rushika Fernandopulle:
About Health Rosetta Group, Iora Health: Iora Health is a healthcare company that helps patients manage their health and navigate the healthcare system.
Suelin Chen
CEO & Co-Founder of Cake
Suelin Chen is the CEO and co-founder of Cake (joincake.com), an online platform for advance care and end-of-life planning that is used by companies including Blue Cross Blue Shield of MA, Harvard Pilgrim, Liberty Mutual, and Massachusetts General Hospital. Suelin earned her BS and PhD from MIT, where she engineered new medical imaging technologies at a translational research lab at MGH. She served as the director of The Lab at Harvard, where she worked with student entrepreneurs and researchers at the Wyss Institute to commercialize their ideas. Suelin then worked as a transaction advisor to healthcare companies at IMS Health Capital before starting Cake.
Follow Suelin Chen:
About Cake: Cake is the world’s largest platform for helping people navigate end-of-life.
Mark Zhang
Co-Founder of Cake
Mark Zhang is the Medical Director of the Digital Innovation Hub at Brigham and Women’s Hospital, Associate Program Director of the Clinical Informatics and Innovation Fellowship at Partners Healthcare, and a Palliative Care consultant at Dana-Farber Cancer Institute. He is the founder of Palliative Care Fast Facts for iOS and Android mobile applications, the co-founder of Cake, a venture backed company focused on advance care planning, and also founded and was the first president of American Medical Informatics Association Clinical Informatics Fellows (ACIF), the national organization for clinical informatics fellows.
Follow Mark Zhang:
About Cake: Cake is the world’s largest platform for helping people navigate end-of-life.
Dean Travers
Co-Founder & Chairman of Luminopia
Dean Travers is the Co-Founder & CEO at Odin.
Follow Dean Travers:
About Luminopia, Odin: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Scott Xiao
Co-Founder & CEO of Luminopia
Scott Xiao is the Co-Founder & CEO at Luminopia.
Follow Scott Xiao:
About Luminopia: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Michael Lin
Co-Founder & Executive Chairman of Reify Health
Michael Lin is the Co-Founder & Executive Chairman at Reify Health.
Follow Michael Lin:
About Reify Health: Reify Health is a cloud-based software company that develops tools for the clinical trial ecosystem.
Jonathan Bush
Founder and CEO of Zus Health
Jonathan Bush is the CEO and Founder of Zus Health. He is also the Chief Executive Officer, President, and Chairman of the Board of Directors. Mr. Bush co-founded athenahealth, Inc. in 1997 and has been a director since our inception. Prior to joining the Company, Mr. Bush served as an EMT for the City of New Orleans, was trained as a medic in the U.S. Army, and worked as a management consultant with Booz Allen & Hamilton. Mr. Bush obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an M.B.A. from Harvard Business School.
Follow Jonathan Bush:
About Firefly Health, Zus Health: Zus Health helps a new wave of healthcare builders to create technologies and services without the usual blockers.
Gaurav Kaushik
Founder of Cascade.bio
Follow Gaurav Kaushik:
About Cascade.bio, ScienceIO: Cascade is rethinking how we interface with biomedical information, to accelerate therapeutic and clinical workflows.
Lara Yuan
Founder of Cascade.bio
Follow Lara Yuan:
About Cascade.bio: Cascade is rethinking how we interface with biomedical information, to accelerate therapeutic and clinical workflows.
Kevin Connors
Executive Director, Founder of Solace Therapeutics
Kevin Connors is an accomplished entrepreneur and venture investor. He has co-founded seven healthcare technology companies, and has had interim CEO roles in nine. These companies have focused on developing proprietary technology to address large un-met medical needs, such as emphysema, low back pain, cerebral aneurysm, and bladder dysfunction. Prior to founding Spray Venture Partners in 1996, Kevin was the founding CEO of Vesica Medical, a company focused on the surgical treatment of female urinary incontinence. Under this leadership, Vesica realized product sales within 18 months of formation and was acquired by Boston Scientific Corporation in 1995. Prior to Vesica, Kevin led medical device investment activity at DSV Partners in Newport Beach, California. Kevin is on the Board of Directors of the New England Venture Capital Association and MassMEDIC, the Massachusetts Medical Device Industry Council. He has served on the Board of Directors of Vesica Medical, Inc. (acquired by Boston Scientific), Masimo Corp., Pilot Cardiovascular (acquired by CR Bard), Circe Biomedical (acquired by ICN Pharmaceuticals), Gamera Bioscience (acquired by Tecan AG), and Endonetics (acquired by Medtronic). In addition to serving on our board, he also serves on the boards of, Facet Solutions, Leptos Biomedical, Solace Therapeutics, Highgate Orthopedics, and Cascade Ophthalmics. Kevin received a B.S. in Electrical Engineering from the University of Notre Dame, an M.S. in Electrical Engineering from the University of Dayton, and an M.B.A. from the Harvard Business School.
Follow Kevin Connors:
About AgenDx Biosciences, Solace Therapeutics, Spray Venture Partners: Solace Therapeutics develops and commercializes non-surgical office-based treatments for common bladder disorders.
Sumit Nagpal
Co-Founder of LumiraDx
Follow Sumit Nagpal:
About Cherish Health, HIMSS, HIMSS, LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Alan D’Andrea
Co-Founder of Cedilla Therapeutics
Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Medicine.
Follow Alan D’Andrea:
About Cedilla Therapeutics, Dana-Farber Cancer Institute: Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Jo Viney
Co-Founder, President and Chief Scientific Officer of Pandion Therapeutics
Follow Jo Viney:
About Pandion Therapeutics: Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Michael Greeley
Co-Founder & Partner of Flare Capital Partners
Michael Greeley was previously a General Partner at [Flybridge Capital Partners](http://www.crunchbase.com/financial-organization/flybridge-capital-partners) whose principle investment focus area is the application of “Big Data” platforms across a number of industry verticals. Michael is most excited about the convergence of healthcare and information technologies and the profound opportunities to transform healthcare. Michael is on the Board of Iora Health and Predilytics, and represented his previous firm on the boards of BlueTarp Financial, MicroCHIPs, PolyRemedy, Predictive Biosciences, SpringLeaf Therapeutics, T2 Biosystems, TARIS Biomedical, and VidSys and led the firm’s investment in lighterliving, Magen BioSciences and Protein Forest. Michael’s blog, On the Flying Bridge, can be found at www.ontheflyingbridge.com. You can follow him on Twitter at www.twitter.com/greels1. Michael founded IDG Ventures Atlantic in 2001 before it transitioned to Flybridge Capital Partners in 2008. Michael served on the board of International Data Group, the flagship Limited Partner for the IDG Ventures global network of funds. Previously, Michael was with Polaris Venture Partners, where he focused on both early-stage and later-stage financings for emerging growth companies. Before Polaris, Michael served as Senior Vice President and Founding Partner of GCC Investments, a $200 million private equity fund. Prior to GCC Investments, Michael was a Vice President and one of the early professionals at Wasserstein Perella & Co., an international merchant bank with a $1.0 billion private equity fund. Additionally, Michael was a member of the Mergers and Acquisitions Department of Morgan Stanley & Co. and worked in the Leveraged Buyout Group of Credit Suisse First Boston. In prior positions, Michael has served on the Boards of a number of public and private companies including FleetCor Technologies (NYSE: FLT), Global TeleSystems Group (NASDAQ: GTSG), El Sitio International (NASDAQ: LCTO), MotherNature.com (NASDAQ: MTHR), Crescent Communications (acquired by Clear Channel), and American Capital Access. Michael received a BA with honors in Chemistry from Williams College and an MBA from Harvard Business School.
Follow Michael Greeley:
About Flare Capital Partners: Flare Capital Partners provides capital for early-stage and emerging healthcare technology companies.
Uli Becker
Co-Founder of Aegle Gear
Uli Becker is Co-Founder of Aegle Gear. Uli is a business executive and investor that supports new businesses that challenge conventions. He also brings 25 years of sporting goods experience to the table. Having worked for adidas, he served in many executive roles including CMO for adidas, as well CEO and President of Reebok, to name a few.
Follow Uli Becker:
About Aegle Gear: Healthcare Apparel built to perform and protect
Jean Sommadossi
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Andrew Needleman
CEO & Founder of DoseSpot
Follow Andrew Needleman:
About Claricode, DoseSpot: E-Prescribing Integration Services
Todd MacLean
Co-Founder and Managing Partner of Silversmith Capital Partners
Todd has spent over 15 years as a growth equity investor prior to co-founding Silversmith Capital Partners. Todd joined Bain Capital Ventures in 2006, serving as a Managing Director upon his return to the firm in 2012 from Silicon Valley where he co-led the growth equity effort at Accel Partners. While at BCV, Todd focused on growth equity investments in the technology sector, with a particular emphasis on application SaaS and information services. Prior to BCV, Todd worked at Summit Partners as an Associate and later Vice President, as well as in operating roles at several private companies, including Synapse Group, the predecessor company to Priceline.com. Todd’s past investment experience includes Appriss (acquired by Insight Venture Partners), Ameritox, Archer (acquired by RSA/EMC), Dealer.com (acquired by Dealertrack), iPay (acquired by Jack Henry & Assoc.), SurveyMonkey, Wrike and Yapstone. He received an AB, cum laude, in English from Dartmouth College and an MBA with Honors from the Wharton School at the University of Pennsylvania. Todd lives with his wife and two children in Newton, MA where he serves on the Board of Trustees of The Park School in Brookline and is actively involved with Cradles to Crayons. He is an avid reader of modern fiction and is slowly sliding back into the misery of being a Red Sox fan that plagued his youth.
Follow Todd MacLean:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Jeff Crisan
Co-Founder and Managing Partner of Silversmith Capital Partners
Follow Jeff Crisan:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Jim Quagliaroli
Co-Founder & Managing Partner of Silversmith Capital Partners
Follow Jim Quagliaroli:
About Absorb LMS, impact.com, Just Women’s Sports, NRG eSports, PDFTron, Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Robert Green
Co-Founder of Genome Medical
Follow Robert Green:
About Genome Medical: Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.
Robert Coffin
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Roy Schoenberg
Co-Founder, Chief Executive Officer & President of Amwell
Roy Schoenberg M.D., MPH founded American Well Inc. and serves as Chief Executive Officer and President of its American Well Systems. Roy Schoenberg founded Carekey, Inc. and served as its President. He served as a Senior Vice President and Chief Internet Solutions Officer at TriZetto, following its acquisition of CareKey in December 2005. He served as Senior Associate of the Center for Clinical Computing, Beth Israel Deaconess Medical Center, Harvard Medical School. He serves as a Director of American Well Corporation. Roy Schoenberg is a frequent speaker at the American Medical Informatics Association and other conferences. He has published a number of scientific papers in leading journals. In 1998, he joined the Harvard-MIT Fellowship Program in Clinical Informatics and earned an additional MPH in Healthcare Management from the Harvard School of Public Health. Roy Schoenberg completed his Medical Training (MD) at the Hebrew University of Jerusalem.
Follow Roy Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Ido Schoenberg
Co-Founder, Chairman, and Chief Executive Officer of Amwell
do serves as the Chairman and CEO of American Well Corporation and oversees the company’s corporate strategy. Ido has a lengthy track record of successfully leading technology companies in the healthcare field. In 1996, together with Phyllis Gotlib, he co-founded iMDSoft, a provider of enterprise software that automates hospital critical care units. He grew the company into a market leader with a large multi-national install base in the U.S., Europe, and East Asia. In 2001, Ido joined CareKey Inc. as Chief Executive Officer and took the company through its acquisition by the TriZetto group. Ido served as TriZetto’s Chief Business Strategy Officer until his departure in the summer of 2006. Ido received his MD from the Sackler School of Medicine.
Follow Ido Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Ian Brady
Co-Founder & CEO of AVA
Ian Brady is the Chief Executive Officer at Hologram Sciences.
Follow Ian Brady:
About AVA, Great Marsh Brewing Company, Hologram Sciences, Plenty: AVA is a personalized, data-driven nutritional coaching solution.
Ihsan Ecemis
Co-Founder & CTO of AVA
Ihsan Ecemis is the CTO at Hologram Sciences.
Follow Ihsan Ecemis:
About AVA, Hologram Sciences: AVA is a personalized, data-driven nutritional coaching solution.
Elliot Cohen
Co-Founder and Chief Product Officer of PillPack
Elliot Cohen is the Co-founder at PillPack.
Follow Elliot Cohen:
About Founder Collective, PillPack: PillPack is a full-service pharmacy that sorts medication by dose and offers door-to-door delivery.
David Coppins
Co-Founder and Chief Executive Officer of IntelyCare
David Coppins is co-founder and CEO of IntelyCare, the intelligent workforce management solution for post-acute healthcare facilities. Prior to starting IntelyCare, David served as president of Virgin Pulse, part of Sir Richard Branson’s Virgin Group. Before Virgin Pulse, David co-founded the college savings company Upromise in 1999. After Sallie Mae bought Upromise for $300M in 2006, David remained with the company and was later named CEO. Earlier in his career, David held various roles in business consulting and private equity at companies including Monitor Deloitte and Monitor Clipper Partners. David has a bachelor’s degree in business management from Brigham Young University.
Follow David Coppins:
About IntelyCare, Virgin Pulse: IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.
Craig Lund
Co Founder & CEO of Mightier
Craig Lund is a Co-Founder and Chief Executive Officer at Mightier.
Follow Craig Lund:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
Jason Kahn
Founder, Chief Science Officer of Mightier
Dr Jason Kahn is the Chief Science Officer and co-founder of Neuromotion. He combines his expertise in developmental psychology and mental health to create video games that help children build emotional strength: the ability to harness their emotions to overcome behavioral challenges. Dr Kahn also holds an appointment at Boston Children’s Hospital and Harvard Medical School, where he creates and researches new technology addressing acute problems in pediatric mental health.
Follow Jason Kahn:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
Alex Adeli
Founder/CEO of Stynt
Follow Alex Adeli:
About Stynt: Simplifying healthcare staffing to enhance the quality of patient care.
Shanel Fields
Founder and CEO of MD Ally
As the child of a volunteer EMT, Shanel Fields was inspired by her father’s experiences as a first responder to launch a healthcare technology company in the 911 space that focuses on ensuring the appropriate use of finite emergency resources and improving long-term patient outcomes. In 2018, she leveraged her mobile and healthcare technology expertise to launch MD Ally, an EMS telemedicine platform that enables collaborative partnerships between public safety and provider organizations for large-scale mobile integrated healthcare initiatives. Shanel has found that driving innovation in the 911 space has fulfilled her desire to positively impact the world around her and improve the health of all citizens, particularly when they’re at their most vulnerable moments. Prior to launching MD Ally, Shanel attended Wharton Business School where she majored in Healthcare Management, Entrepreneurship and Innovation, as well as worked alongside life-long EMS researchers to study patient ER utilization and first responder advocacy. For more than a decade, she’s worked for innovative companies like AT&T and athenahealth, where she has scaled and led impact-focused growth teams focused on enterprise health systems, payers, and independent health entities.
Follow Shanel Fields:
About MD Ally: MD Ally is a telehealth company that enables a virtual response tier for 9-1-1.
Daphne Zohar
Founder, CEO of PureTech Health
Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.
Follow Daphne Zohar:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
Luk Vandenberghe
Co-Founder of GenSight Biologics
Follow Luk Vandenberghe:
About Affinia Therapeutics, Akouos, Broad Institute, GenSight Biologics, Grousbeck Gene Therapy Center, Harvard Medical School, Harvard University, Massachusetts Eye and Ear Infirmly: GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Daniel Palestrant
Founder & CEO of Par8o
Daniel Palestrant studied at Johns Hopkins, Duke University, and Harvard Medical School. He co-founded SERMO, the largest online physician community in the world, which was acquired in 2013.
Follow Daniel Palestrant:
About Par8o: The current healthcare crisis is a uniquely American challenge and ultimately will be solved with a uniquely American solution.
Ravi Kapur
Founder of Torpedo Diagnostics
Ravi Kapur is a scientist, engineer, and entrepreneur with 20 years of experience in developing and commercializing nascent technologies from academic laboratories. He is an Entrepreneur-in-Residence and directs the Innovation Team at Massachusetts General Hospital in Boston. He led the engineering team at MGH in development of the CTC-iChip. He has co-founded and built successful companies with innovative technology from MGH, MIT, Princeton, and Carnegie Mellon. He is currently the CEO of MicroMedicine Inc., a spinout from MGH. Dr. Kapur trained as a Bioengineer at Clemson University and cut his teeth in technology and product development at the United States Naval Research Laboratory in Washington DC.
Follow Ravi Kapur:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Shyamala Maheswaran
Founder of Torpedo Diagnostics
Shyamala Maheswaran is an Associate Professor in Surgery at Harvard Medical School and the Scientific Director for the Center for Cancer Risk Assessment at the Massachusetts General Hospital. She is an authority in breast cancer biology and in molecular biology. Her long-term interest in the field of cancer biology has led to her leadership of collaborations with physicians, scientists and engineers, focused on the molecular applications of the CTC-iChip technology. Dr. Maheswaran graduated from the University of Peradeniya in Sri Lanka and received her doctorate in Biochemistry and Molecular Biology from Boston University, MA. Her research includes several high profile publications ranked in the top 1% of the academic field of Molecular Biology and Genetics based on a highly cited threshold for the field and publication year.
Follow Shyamala Maheswaran:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Geoff MacKay
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Elisabet de los Pinos
Founder and CEO of Aura Biosciences
Follow Elisabet de los Pinos:
About Aura Biosciences: Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Robin Smith
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Kate Blanchard
Chief Operating Officer / Founder of ORIG3N
Follow Kate Blanchard:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Peter Hartzbech
Founder & CEO of iMotions A/S
Peter Hartzbech passion is global entrepreneurship and building companies. Driven by a desire to make a difference in the world, he embarked upon his entrepreneurial career by starting his first venture at the age of 25. Prior to founding iMotions, he worked in Ernst & Young Denmark and Venture Cup Denmark, where he advised start-up companies on business plans, strategic and financial issues. In December 2006, Peter was appointed by Red Herring Magazine as Top 25 under 35, where the Magazine appoints Notable Entrepreneurs under 35. Peter’s positive attitude and global vision have been the main driving forces behind iMotions’ rapid growth and expansion.
Follow Peter Hartzbech:
About iMotions A/S: iMotions A/S develops and provides biometric platforms, neuromarketing, psychology, VR, and engineering solutions.
Rudolf Jaenisch
Co-Founder of Fate Therapeutics
Rudolf Jaenisch is a founding member of the Whitehead Institute and a pioneer of developmental biology. He was the first to create a transgenic mouse, a technical achievement that changed the course of biomedical research by enabling the creation of animal models of human diseases. Dr. Jaenisch was also one of the first scientists to reprogram fully mature adult cells, like a skin cell, to become stem-like. Called induced pluripotent stem cells (iPSCs), this technology removed the dependence on embryos as a source of stem cells. At the Whitehead Institute, Dr. Jaenisch has been pursuing an understanding of epigenetic regulation and reprogramming, which has lead him to make principal discoveries in the field of stem cells. Dr. Jaenisch has coauthored more than 300 research papers, was appointed to the National Academy of Sciences and has received numerous prizes and recognitions, including First Peter Gruber Foundation Award in Genetics (2001), Robert Koch Prize for Excellence in Scientific Achievement (2002), BrupbacherFoundation Cancer Award (2003), Vilcek Prize (2007), and Massry Prize (2008).
Follow Rudolf Jaenisch:
About Fate Therapeutics, Fulcrum Therapeutics: Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Rich Gliklich
Founder and CEO of OM1
Rich Gliklich is the Founder and CEO at OM1.
Follow Rich Gliklich:
About Cyft, OM1: OM1 is a healthcare technology company that leverages real-world clinical data for medical research and personalized medicine.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Ronald A. DePinho
Co-Founder & Co-Chair of Asylia Therapeutics
Ronald DePinho is the Co-Founder and Co-Chair of Asylia Therapeutics.
Follow Ronald A. DePinho:
About Asylia Therapeutics, Karyopharm Therapeutics, Metamark Genetics, National Academy of Sciences, Nirogy Therapeutics, Stellanova Therapeutics, The University of Texas M.D. Anderson Cancer Center: Asylia Therapeutics is a biotech company focused on novel immune-modulating therapies for autoimmune, cancer, and infectious diseases.
Ed Tourtellotte
Founder & CTO of 4G Clinical
Ed Tourtellotte is the Founder and CTO at 4G Clinical.
Follow Ed Tourtellotte:
About 4G Clinical: 4G Clinical provides software and services for clinical drug trials specifically in randomization and trial supply management (RTSM).
Sebastian Schneeweiss
Co-Founder & Science Lead of Aetion
Sebastian Schneeweiss is Professor of Medicine and Epidemiology at Harvard Medical School and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics of the Department of Medicine, Brigham and Women’s Hospital, a world-leading research and training center. His research is funded by multiple NIH, PCORI, and FDA grants and focuses on the comparative effectiveness and safety of biopharmaceuticals. He has developed analytic methods to improve the scientific validity of epidemiologic analyses using complex longitudinal healthcare databases particularly for newly marketed medical products. Applying such methods transparently and in rapid cycles for sequential medication effectiveness monitoring is the overarching theme of his research. His work is published in >300 articles, many of them in high-ranking journals. He is Aetion Inc.’s Science Lead were he develops a worldwide network of rapid-cycle analytics platforms that produces evidence fit for decision making in healthcare. Dr. Schneeweiss is Director of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER and Co-Chair of the Methods Core of the FDA Sentinel program. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and was inaugural member of the Methods Committee of the Patient Centered Outcomes Research Institute. He was President of the International Society for Pharmacoepidemiology, inaugural member of the PCORI Methods Committee and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology. At Harvard he teaches courses on Database Analytics for Pharmacoepidemiology and on Effectiveness Research in Longitudinal Healthcare Databases among others. He received his medical training at the Ludwig-Maximilians University of Munich and his doctoral degree in pharmacoepidemiology from Harvard.
Follow Sebastian Schneeweiss:
About Aetion, Brigham and Women’s Hospital, Harvard Medical School: Aetion provides real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers.
Shrenik Jain
Founder & CEO of Marigold Health
Follow Shrenik Jain:
About Marigold Health: Marigold Health uses chat support groups to make substance use treatment more engaging and personalized for vulnerable populations.
Stuart Koman
Founder, President & CEO of Walden Behavioral Care
Stuart Koman, Ph.D. is a founder and the Chief Executive of Walden Behavioral Care and its non-profit sister corporation, the Walden Center for Education and Research. Dr. Koman is a veteran health care manager with more than 30 years of experience leading and developing several behavioral health care companies. While all of these companies have become successful businesses under his leadership, Dr. Koman attributes much of this success to another common theme: they have all taken seriously their mission of providing innovative, compassionate and coordinated services to previously under served populations and families. Walden Behavioral Care is the most recent example as it has quickly become the leading provider of services for individuals with eating disorders in New England through its multi-level, multi-site system of care. In the nine year period 2003-2012, Walden has become a state of the art system of care providing some 40,000 service units annually at its primary campus in Waltham (MA) and satellite centers in Braintree (MA), Worcester (MA), Northampton (MA) and South Windsor, Connecticut. Dr. Koman began his professional career in 1985 when he was appointed senior clinician and then Director of Adolescent Programs at Charles River Hospital (CRH) in Wellesley, MA. Over the next 10 years (1985 to 1996), he led two companies in achieving significant clinical and business outcomes. The first company, Charles River Management (CRHM), a subsidiary of CRH, grew out of the work of Dr. Koman and others in developing innovative treatment models for adolescents in hospital settings. Dr. Koman and his colleagues were among the first to recognize the central importance of the family in treatment program design. Many of these and related ideas were published in the Handbook of Adolescents and Family Therapy, an effort in which Dr. Koman wrote several chapters and served as co-editor. In 1990, Dr. Koman co-founded the managed health care company, Choate Health Systems, Inc. (CHSI). Similar to the approach at Charles River, Choate provided integrated delivery of behavioral health care through a full continuum of treatment services operating under one administration. As this model proved highly adaptive in the emerging world of managed care, Choate expanded rapidly, and this led to the formation of Choate Health Management, Inc. (CHMI) and Choate Psychiatric Associates, P.C. (CPA). Having successfully managed the transition in health care reimbursement approaches, Dr. Koman was asked to assist the profession of psychology to do the same and subsequently served on the Governing Board of the American Psychological Association’s practice division from 1992-2000. After leaving Choate in 1995, Dr. Koman started Koman Associates, a firm that focuses on leaders and leadership issues in government, health care and business. At the same time, Dr. Koman served as Senior Clinical Adviser for Public Consulting Group providing strategic planning and systems re-engineering to state agencies throughout the United States. Dr. Koman continues his involvement with both of these organizations albeit on a much reduced basis once Walden was established in 2003. Dr. Koman earned his Bachelor of Science degree from Trinity College and his Ph.D. from Duke University.
Follow Stuart Koman:
About Walden Behavioral Care: Walden Behavioral Care, a Waltham, Mass.-based provider of behavioral health services for individuals with eating disorders.
Kevin Ohashi
Co-Founder of Kinetxx
Follow Kevin Ohashi:
About DirectDerm, Kinetxx: Kinetxx, Inc. is a Digital Healthcare Company headquartered in Cambridge, MA partnered with leading Orthopaedic Surgeons.
Mark Stott
Co-Founder of Kinetxx
Follow Mark Stott:
About Kinetxx: Kinetxx, Inc. is a Digital Healthcare Company headquartered in Cambridge, MA partnered with leading Orthopaedic Surgeons.
Andrew Miller
Founder & COO of Karuna Therapeutics
Dr. Miller is a Founder, Director, and the Chief Operating Officer of Karuna Pharmaceuticals. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston. Previously, Dr. Miller was a Vice President at PureTech Health for 8 years, most recently as Vice President, the COO of Tal Medical, and the acting-COO of Entrega where he serves on the board. Dr. Miller completed his doctoral work in Chemical Engineering at the Massachusetts Institute of Technology and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. Dr. Miller received a B.S. in Chemical Engineering from the University of Illinois with highest honors.
Follow Andrew Miller:
About Karuna Therapeutics, Tal Medical: Karuna Therapeutics is a Massachusetts-based developer of drugs for the treatment of schizophrenia.
David Berry
Founder and CEO of Valo Health
David Berry, M.D., PhD., is an American inventor, entrepreneur, venture capitalist and CEO. Berry has co-founded and helped build over 10 companies in life sciences, technology, and sustainability. In 2007, he was named as the Innovator of the Year from the MIT Technology Review TR35 list of one of the top 35 innovators in the world under the age of 35. He was selected as a 2014 Young Global Leader by the World Economic Forum. In 2007, Berry founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. Berry served as President and CEO of the company through April 2009, and currently serves on the Board of Directors. Joule is pioneering solar fuels through a new technology that coverts sunlight, carbon dioxide, and salt water into drop-in fuels for prices as low as $20. In March 2010 and again in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2011. Joule’s unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule’s technology has now been successfully scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Berry has been recognized multiple times as one of the top people in bioenergy by Biofuels Digest. In 2009, Berry founded Pronutria, which is pioneering a new approach to unlock the vast untapped therapeutic potential of proteins in the diet. Berry served as President and CEO through March 2012. Pronutria has built a proprietary database that contains over 1 billion food proteins, and leverages 40 years of clinical data that validates the pharmacological activity of particular amino acid combinations to identify proteins that, when delivered orally, act as prodrugs. The protein delivery form allows for of important drug-like properties including pharmacokinetic control and improvement of physiochemical features. Pronutria has advanced two of its ProNutrein™ into clinical trials. In 2011, Berry founded Seres Health, a company that develops a new class of therapeutics based on insights into the biology of the human microbiome. Seres Health has developed a new approach to functionally assess the changes of the microbiome associated with disease, and identifies a consortia of organisms that can catalyze a shift to health. Seres has advanced is lead into the clinic for recurrent C. difficile. In 2005, Berry co-founded LS9, with Chris Somerville, Jay Keasling, and George M. Church, which uses synthetic biology to engineer microorganisms to covert sustainable, plant-based materials into low-carbon fuels and chemicals. LS9 has successfully built on technologies he invented with other co-founders to produce a scalable platform for renewable fules and chemicals. This technology was successfully scaled to a fully operational 135,000L facility in Okeechobee, Florida. The impact and importance of LS9’s technology led to its being named a Technology Pioneer by the World Economic Forum in 2008 and its being awarded the Presidential Green Chemistry Challenge Award in 2010, the U.S. Environmental Protection Agency’s highest environmental honor. LS9 was acquired by Renewable Energy Group in 2014. Berry joined Flagship Ventures, a Cambridge, Massachusetts based venture capital firm that invests in and founds companies in healthcare and sustainability, in 2005 where he is a Partner. Berry has been described “a rising star of the Boston-area venture capital scene,” and “one of the most brilliant thinkers.” Berry serves on the Board of Directors of Joule Unlimited, Seres Health, Pronutria, Eleven Biotherapeutics (NASDAQ: EBIO), and Symbiota. Berry has been an author of 14 scientific papers and over 60 patent applications.
Follow David Berry:
About Axcella, Evelo Biosciences, Flagship Pioneering, Hackley School, Indigo, Joule Unlimited Technologies, Omega Therapeutics, Seres Therapeutics, Seres Therapeutics, Valo Health: Valo Health uses human-centric data and machine learning-anchored computation to transform the drug discovery and development process.
Agneta Breitenstein
Founder & CEO of FOLX Health
A.G. is a co-founder of Humedica and serves as Chief Product Officer, Optum Analytics. Prior to Humedica, she was a Director at Leerink Swann, a leading health care investment bank. Previously, A.G. co-founded the Institute for Health Metrics (IHM). In 2000, she co-founded PrivaSource, which focused on the de-identification of health data. A.G. also served as Chair of the Massachusetts Work Group on the Privacy of Medical Records and was the primary drafter of the Massachusetts “Act to Protect the Privacy of Medical Records.” A.G. teaches ethics with Professor Marc Roberts at the Harvard School of Public Health. She received her MPH from Harvard University, her JD from the University of Connecticut, and her bachelor’s degree from Yale University.
Follow Agneta Breitenstein:
About FOLX Health: FOLX Health provides digital health care services designed for the LGBTQIA+ community.
Arman Serebrakian
Co-Founder of Statum Systems
Arman Serebrakian is a Plastic and Reconstructive Surgery Resident at Harvard Plastic Surgery. He is also the Co-Founder and Medical Consultant at Statum Systems.
Follow Arman Serebrakian:
About Statum Systems: Statum Systems solves a significant problem plaguing healthcare: inefficient and unreliable communication among healthcare practitioners.
Ara Nazarian
Co-Founder of Statum Systems
Ara Nazarian is a Principal Investigator at Beth Israel Deaconess Medical Center,. He is also the Chief Science Officer and Co-Founder at Statum Systems.
Follow Ara Nazarian:
About Statum Systems: Statum Systems solves a significant problem plaguing healthcare: inefficient and unreliable communication among healthcare practitioners.
David Ting
Founder & Chief Technology Officer of Imprivata
Follow David Ting:
About Imprivata, Nylas: Imprivata helps health organizations secure their networks, and provides single sign-on solutions for health information access.
Jeannie T. Lee
Scientific Co-Founder of Fulcrum Therapeutics
Jeannie T. Lee is an Investigator of the Howard Hughes Medical Institute and Professor of Genetics at Harvard Medical School and the Massachusetts General Hospital. She is also a Co-Director of the Epigenetics Initiative at Harvard Medical School and at the Massachusetts Geneteral Hospital.
Follow Jeannie T. Lee:
About Fulcrum Therapeutics, Massachusetts General Hospital: Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients.
Sean Power
Founder & CEO of karmadata
Follow Sean Power:
About karmadata, Power Fund Partners, PrescribeWellness, WIRB-Copernicus Group: Healthcare (Big) Data Simplified
Brendan Kelleher
Chief Data Officer, Co-Founder of karmadata
Karmadata is Healthcare (Big) data simplified. It’s free to join. Upgrade to Premium for more features and data. Or Contact us to enroll your company with Plus and enjoy a Private Sandbox area in our data cloud for your company only with unlimited access. Not ready join? Watch a live demo of karmadata to learn more.
Follow Brendan Kelleher:
About karmadata: Healthcare (Big) Data Simplified
Will Cowen
Co-Founder & General Partner of LRVHealth
Will Cowen is an investor and operator with decades of experience building successful digital health and medtech companies. He co-founded LRVHealth in 2000 and has led the firm’s investments in prominent companies including Convergent Dental, GetWellNetwork, LifeImage, MedVentive (now part of NASDQ: CHNG), Phreesia (NASDAQ: PHR) and SilverCloud. Prior to LRVHealth, Will co-founded and was CEO of NaviNet (sold to Highmark and other BCBS plans), CEO of Pegasus Medical (sold to McKesson), and VP of Thermocell (sold to the Hunter Douglas Company). Will earned a B.A. from the University of Colorado and M.B.A. from the Massachusetts Institute of Technology.
Follow Will Cowen:
About LRVHealth: LRVHealth is an “Inside Healthcare” venture capital platform established in 2000 by a team of healthcare investors, operators & advisors
Alexis Normand
Head of Blockchain Consortium and Co-Founder of Embleema
Alexis Normand is the Head of Blockchain Consortium and Co-Founder at Embleema.
Follow Alexis Normand:
About Embleema, Greenly: Accelerating the availability of new treatments to the 350 million rare disease sufferers around the world.
Gajen Sunthara
Founder of 1upHealth
Follow Gajen Sunthara:
About 1upHealth: 1upHealth is a health-tech company that builds products for the future of healthcare.
Aaron O’Hearn
Co-Founder & CEO of Worthright
Aaron is the Co-Founder and CEO of Worthright.
Follow Aaron O’Hearn:
About Worthright: Worthright is a family of aging adults plan.
Daniel Levner
Co-Founder & Chairman of the Scientific Advisory Board of Sight Diagnostics
Daniel Levner is Emulate’s Chief Technology Officer. Prior to joining Emulate’s founding team, he was a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he led the advanced engineering team responsible for developing Emulate’s Organs-on-Chips platform. Levner played a key leadership role in managing the multidisciplinary Organs-on-Chips team by formulating innovative approaches for fostering close collaboration and in-depth exchange between biologists and engineers. Levner brings this tight integration of disciplines to Emulate, where it is a defining part of the company’s culture. Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing tools, and multiplexed analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company, and earlier in his career, an optical telecommunications startup company. Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 20 issued and pending patents.
Follow Daniel Levner:
About Emulate, Sight Diagnostics: Blood diagnostics company that uses machine vision and AI to transform health systems and outcomes through fast and accurate blood testing.
Beau Mann
Founder & CEO of Sober Grid
Follow Beau Mann:
About Sober Grid: Sober Grid is a digital health application focused on creating mobile communities that engage people into chronic disease management.
Warren Kett
Co-Founder of Avitide
Warren Kett is the Co-Founder at Avitide, Inc.
Follow Warren Kett:
About Avitide: Avitide develops affinity purification solutions for biopharmaceutical companies.
Leo Qian
Co-Founder & Platform Chemistry and Biology of Entrada Therapeutics
Follow Leo Qian:
About Entrada Therapeutics: Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Sombit Mishra
Founder & CEO of QMedic
Sombit brings 10 years of experience in Web/Mobile/Wearable UX, strategy, product management, marketing, and business development to QMedic. Previously, he conceived, designed, and launched an obesity management and telemedicine application in partnership with one of the world’s leading hospitals. He has been invited to speak at numerous conferences on mobile health and healthy aging, including AARP, Health 2.0, Aging 2.0, the Cleveland Clinic Summit, and Athenahealth’s More Disruption Please. In 2013, Sombit was selected as a TEDMED Innovation Scholar and 1 of 14 Emerging Innovators by American Express and the Ashoka Foundation. While in graduate school at MIT, Sombit was awarded the Patrick J. McGovern Prize for outstanding contributions to the student community, which included raising over $1M in sponsorships for MIT companies across health, software, and clean technology. He continues to serve as a business mentor to hundreds of executives through the MIT Trust Center for Entrepreneurship and Sloan Fellows programs. Sombit completed his MBA from the MIT Sloan School of Management, an MSc from the London School of Economics, and a BA from Northwestern University.
Follow Sombit Mishra:
About QMedic: QMedic is an intelligent medical alert & routing service to keep care in network and at home.
Stefano Ciampolini
Founder of NephroNet
Stefano is a healthcare entrepreneur and co-founder of Healthcare Capital Partners, a London based private equity and corporate finance advisory firm specializing in life sciences and healthcare. He began his professional career with his family’s group of companies, which included private clinics and diagnostic equipment manufacturing in Italy, France and the United States. In 1999, he founded NephroNet, a chain of independent dialysis centres, which was acquired by Baxter Inc. in 2001. Since 2007 he has served as CEO of the Renal Services Group, a dialysis services company based in London which he founded. Stefano is a founder, board member and investor in several healthcare ventures and private equity funds focusing on healthcare investments in Europe and the US including General Genetics Corporation, a US genetic company, and biofficient.com, a biotech e-platform company. He is currently a partner at Boss Group, a global investment firm.
Follow Stefano Ciampolini:
About EGS Healthcare Capital Partners, NephroNet, Renal Care Group, UV Light Care: We are a network of experienced academic and private clinical trial centers.
